{"id":"valemetostat","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Histone-lysine N-methyltransferase EZH2","category":"target"},{"label":"EZH2","category":"gene"},{"label":"EZH1","category":"gene"},{"label":"Active","category":"status"},{"label":"Relapsed or refractory T-cell leukemia-lymphoma","category":"indication"},{"label":"Daiichi Sankyo Company, Limited","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Daiichi Sankyo","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=VALEMETOSTAT","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:12:59.187424+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Valemetostat","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:13:06.377964+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:13:04.452370+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VALEMETOSTAT","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:13:05.328304+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4594405/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:13:06.024749+00:00"}},"allNames":"ezharmia","offLabel":[],"synonyms":["valemetostat","valemetostat tosilate","ezharmia","DS-3201"],"timeline":[{"date":"2022-09-26","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Daiichi Sankyo Company, Limited)"}],"approvals":[{"date":"2022-09-26","orphan":true,"company":"DAIICHI SANKYO COMPANY, LIMITED","regulator":"PMDA"}],"brandName":"Ezharmia","ecosystem":[{"indication":"Relapsed or refractory T-cell leukemia-lymphoma","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Histone-lysine N-methyltransferase EZH2","targets":[{"gene":"EZH2","source":"DrugCentral","target":"Histone-lysine N-methyltransferase EZH2","protein":"Histone-lysine N-methyltransferase EZH2"},{"gene":"EZH1","source":"DrugCentral","target":"Histone-lysine N-methyltransferase EZH1","protein":"Histone-lysine N-methyltransferase EZH1"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Ezharmia is a small molecule inhibitor of Histone-lysine N-methyltransferase EZH2, a key enzyme in the polycomb repressive complex 2 (PRC2) complex, which plays a crucial role in gene silencing and cancer cell proliferation."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Valemetostat","title":"Valemetostat","extract":"Valemetostat is a drug used for the treatment of adult T-cell leukemia/lymphoma (ATL)."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5724","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=VALEMETOSTAT","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VALEMETOSTAT","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Valemetostat","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T16:07:15.361080","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:13:07.688069+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"tazemetostat","drugSlug":"tazemetostat","fdaApproval":"2020-01-23","patentExpiry":"Sep 12, 2031","patentStatus":"Patent protected","relationship":"same-target"}],"genericName":"valemetostat","indications":{"approved":[{"name":"Relapsed or refractory T-cell leukemia-lymphoma","source":"DrugCentral","snomedId":110007008,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"tazemetostat","brandName":"tazemetostat","genericName":"tazemetostat","approvalYear":"2020","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT05683171","phase":"PHASE1,PHASE2","title":"A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-05-19","conditions":["Lymphoma"],"enrollment":60,"completionDate":"2027-09-30"},{"nctId":"NCT06632977","phase":"PHASE2","title":"Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-02-06","conditions":["Castration-Resistant Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":474,"completionDate":"2034-10-11"},{"nctId":"NCT03930953","phase":"PHASE1,PHASE2","title":"A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2019-05-20","conditions":["Lymphoma, Non-Hodgkin"],"enrollment":438,"completionDate":"2028-02-09"},{"nctId":"NCT04842877","phase":"PHASE2","title":"Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2021-06-11","conditions":["Lymphoma, B-Cell"],"enrollment":141,"completionDate":"2026-10"},{"nctId":"NCT07244341","phase":"PHASE1","title":"A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-12-03","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":60,"completionDate":"2029-11-30"},{"nctId":"NCT06244485","phase":"PHASE1","title":"A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-02-16","conditions":["Advanced Solid Tumor"],"enrollment":210,"completionDate":"2028-11-01"},{"nctId":"NCT05633979","phase":"PHASE1","title":"Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-02-09","conditions":["Breast Cancer"],"enrollment":17,"completionDate":"2032-12-31"},{"nctId":"NCT07303387","phase":"PHASE2","title":"Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2026-02-28","conditions":["Solid Tumor Malignancies","Clear Cell Endometrial Carcinoma","Ovarian Cancer"],"enrollment":900,"completionDate":"2032-02-28"},{"nctId":"NCT04703192","phase":"PHASE2","title":"Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2021-06-03","conditions":["Relapsed/Refractory Peripheral T-Cell Lymphoma","Adult T Cell Leukemia/Lymphoma"],"enrollment":155,"completionDate":"2027-02-19"},{"nctId":"NCT04388852","phase":"PHASE1","title":"DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-20","conditions":["Aggressive Variant Prostate Carcinoma","Castration-Resistant Prostate Carcinoma","Metastatic Clear Cell Renal Cell Carcinoma","Metastatic Malignant Solid Neoplasm","Metastatic Prostate Carcinoma","Metastatic Urothelial Carcinoma","Stage IV Prostate Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8"],"enrollment":65,"completionDate":"2026-12-31"},{"nctId":"NCT06807632","phase":"PHASE1","title":"A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-01-29","conditions":["Extensive-stage Small-cell Lung Cancer"],"enrollment":24,"completionDate":"2027-01"},{"nctId":"NCT06644768","phase":"PHASE1,PHASE2","title":"A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-10-30","conditions":["Non-small Cell Lung Cancer","Lung Cancer"],"enrollment":137,"completionDate":"2030-04-30"},{"nctId":"NCT06294548","phase":"PHASE1,PHASE2","title":"A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-07-29","conditions":["Hepatocellular Carcinoma"],"enrollment":45,"completionDate":"2028-08-28"},{"nctId":"NCT05879484","phase":"PHASE1,PHASE2","title":"Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2025-07-09","conditions":["Sinonasal Cancer","Squamous Non-small Cell Lung Cancer","Lung Cancer","Head and Neck Squamous Cell Carcinoma","Head and Neck Carcnimona","Head and Neck Cancer"],"enrollment":0,"completionDate":"2025-07-09"},{"nctId":"NCT04102150","phase":"PHASE2","title":"Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2019-11-21","conditions":["Adult T-cell Leukemia/Lymphoma"],"enrollment":25,"completionDate":"2024-10-27"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"60RD0234VE","INN_ID":"10747","UMLSCUI":"C5239419","chemblId":"CHEMBL4594405","ChEMBL_ID":"CHEMBL4597193","KEGG_DRUG":"D11551","PUBCHEM_CID":"126481870","IUPHAR_LIGAND_ID":"12282"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Daiichi Sankyo Company, Limited","relationship":"Current Owner"}],"publicationCount":62,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Daiichi Sankyo","companyId":"daiichi-sankyo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ezharmia, also known as Valemetostat Tosylate, is a small molecule. It is a compound with the synonyms Valemetostat Tosylate and Valemetostat Tosilate.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2022-09-26T00:00:00.000Z","mah":"DAIICHI SANKYO COMPANY, LIMITED","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":9,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:13:07.688069+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}